Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis ; volume:29 ; number:1 ; day:19 ; month:12 ; year:2024 ; pages:1-9 ; date:12.2024
European journal of medical research ; 29, Heft 1 (19.12.2024), 1-9, 12.2024

Urheber
Scaglione, Vincenzo
Gardin, Samuele
Sasset, Lolita
Presa, Nicolò
Rossetto, Alberto
Boemo, Deris Gianni
Silvola, Sofia
Restelli, Umberto
Cattelan, Annamaria
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s40001-024-02154-2
URN
urn:nbn:de:101:1-2503020600578.830004920745
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:36 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Scaglione, Vincenzo
  • Gardin, Samuele
  • Sasset, Lolita
  • Presa, Nicolò
  • Rossetto, Alberto
  • Boemo, Deris Gianni
  • Silvola, Sofia
  • Restelli, Umberto
  • Cattelan, Annamaria
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition

The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition

Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes

Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes

Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model

Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy

Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms

Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Verbundene Objekte